1AI 16.7% 0.7¢ algorae pharmaceuticals limited

hopefully the opposite is true, if the early onset is the only...

  1. 2,980 Posts.
    lightbulb Created with Sketch. 69
    hopefully the opposite is true, if the early onset is the only period of effective outcome then it limits how well the treatment works and confines its use or when it can be used .....dopa doesnt chelate the way it is interpreted in some studies cos if it did then (likely) the alpha-synuclein protein would not have any advantage and constantly chelate new events and plaques would be limited to where the patient only has Parkinsonism

    the patients who have a matured PD are just as good for the trial as they are less likely to recede the damage and more likely to struggle with any other form of therapy whereas early stage can or may show relief from topical treatments without receiving longterm benefit from those treatments. so, in that respect the longer term PD patients give a better insight into the effectiveness of NTcell
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
0.001(16.7%)
Mkt cap ! $11.81M
Open High Low Value Volume
0.6¢ 0.7¢ 0.6¢ $1.529K 244.8K

Buyers (Bids)

No. Vol. Price($)
4 179444 0.6¢
 

Sellers (Offers)

Price($) Vol. No.
0.7¢ 1964350 8
View Market Depth
Last trade - 14.16pm 31/10/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.